GENMARK DIAGNOSTICS, INC.

4.21 -0.34 (-8.08%) Sell

GNMK is a falling knife, continues to bleed every investor trying to catch it

13 min read

GNMK significantly underperformed today. On a longer term basis, investors in GENMARK DIAGNOSTICS, INC. made +0.09% per day. Monday's performance of -8.08% was a significant underperformance compared to it's daily average.

[Themes containing GNMK]

GNMK showed a strong down trend over the last 3 months. During this period GNMK returned -44.53% and saw a maximum drawdown of -47.77%. There was a short signal during this period which returned +39.86%.

Trend

GNMK has been outperforming the SP500 index in recent time. Over the last 2 years 11 months and 10 days, GNMK underperformed the SP500 index on 51% days.

GNMK returned losses on 57% days in the last three months. During this time, it delivered on average -0.88% per day. It delivered it's best daily return of +9.73%, during this period, on Wednesday, 7 Nov, 2018. There was initially a bearish trend during this period which started on 26 Sep, 2018 and went on till 3 Oct, 2018. The trend delivered -17.39% losses to investors. This was followed by a bullish trend that started on 13 Nov, 2018 and ended on 26 Nov, 2018. This bullish trend delivered +14.39% to investors.

On monthly basis, GNMK delivered profits and losses in equal number of months. GNMK delivered profits less regularly than SP500 index. GNMK significantly outperformed SP500 index in Mar 2018, when it returned +32.04% compared to +4.75% returned by SP500 index during it's best month in the last one year - Jan 2018. GNMK had a longer winning streak of losing months than SP500 index. It went down in 4 straight months (from Sep 2018 to Dec 2018) during which period it delivered -52.34%. It is interesting to note that both GNMK and SP500 index significantly outperform during months when quarterly/annual results are announced.

Financial support is one thing, but I always think what becomes really sacrificial is your time.
-- Cliff Richard

GNMK is becoming more volatile overall. In comparison, the SP500 index is seeing a rise in volatility. During the last three months, there was a significant surge in GNMK's volatility from 24 Sep, 2018 to 8 Oct, 2018. While there was a significant surge in the SP500 index's volatility from 19 Sep, 2018 to 29 Oct, 2018.

Advanced/professional short-term investors should note that GNMK has significant positive skewness in it's return distribution. This indicates that investors can expect GNMK to recover from drawdowns quickly. Which makes GNMK a good candidate for investing on short-term bullish trends or even counter-trends hoping for a pull-back.

SP500 index has more chance of extreme outcomes than GNMK. Therefore, SP500 must receive a lower allocation than GNMK in your portfolio. GNMK usually has shorter drawdown period than the SP500 index.

Based on your interest in GNMK you may find it interesting to know that APRN, NSPR and AYTU have all shown remarkable performance and qualify to be on every investor's watchlist.

Want to improve your Portfolio's performance?

Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
Following
Symbol Price {{retType}} | Tr.
{{detail.symbol}} {{detail.close}} {{detail.priceChange}}  {{detail.pctChange}}%  {{detail.name}} {{detail.trend}} 
 
If you liked what you read here ...

... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.

All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.

We want to empower investors with all the tools and analysis required by them to make a rational investment decision.

If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute
Share with friends   WhatsApp   Facebook   Twitter